VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED
Clinical trials for VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a triple therapy beat cervical cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…
Matched conditions: VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Matched conditions: VAGINAL SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC